Now showing items 1-1 of 1

    • A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease 

      Wun, Ted; Soulieres, Denis; Frelinger, Andrew Lawrence; Krishnamurti, Lakshmanan; Novelli, Enrico M; Kutlar, Abdullah; Ataga, Kenneth I; Knupp, Charles L; McMahon, Lillian E; Strouse, John J; Zhou, Chunmei; Heath, Lori E; Nwachuku, Chuke E; Jakubowski, Joseph A; Riesmeyer, Jeffrey S; Winters, Kenneth J (BioMed Central, 2013)
      Background: Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet ...